Volume 19, Number 9—September 2013
Dispatch
Powassan Meningoencephalitis, New York, New York, USA
Table
Test | Test result, month |
|
---|---|---|
Patient 1, 2009 | Patient 2, 2012 | |
West Nile virus IgM ELISA | Nonreactive, Feb | Nonreactive, May |
Eastern equine encephalitis virus IgG IFA | <16, Feb | <16, May |
Western equine encephalitis virus IgG IFA | <16, Feb | <16, May |
California serogroup IgG IFA | <16, Feb | <16, May |
St. Louis encephalitis virus IgG IFA | <16, Feb | <16, May |
rPOW-E polyvalent MIA† (titer) | Reactive, Feb | Reactive, May |
Powassan PRNT (titer) | + (20), Feb | + (280), early May |
+ (320), Mar | + (320), late May | |
+ (160), early Jun | ||
+ (10), late Jun | ||
Powassan RT-PCR CSF | Not done | – |
*POWV, Powassan virus; RT-PCR, reverse transcription PCR; CSF, cerebrospinal fluid; IFA, immunofluorescent assay; MIA, microsphere immunoassay; PRNT, plaque reduction neutralizing test;; +, positive; –, negative.
†A fluorescent MIA technique using recombinant POWV envelope glycoprotein antigen to detect IgG, IgA, and IgM.
1These authors contributed equally to this article.
Page created: August 20, 2013
Page updated: August 20, 2013
Page reviewed: August 20, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.